NCT06566092进行中（未招募）1 期
A Phase 1, Multicenter, Open-label, 2-stage, Single-arm Study to Evaluate the Safety and Tolerability of an Autologous Tumor-infiltrating Lymphocytes (TIL) Regimen and Preliminary Antitumor Activity of TIL in Pediatric, Adolescent, and Young Adult Participants With Relapsed or Refractory Solid Tumors
适应症
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 40
- 试验地点
- 7
- 主要终点
- Incidence rate of Treatment-Emergent Adverse Events
研究概览
简要总结
This study is planned to test the safety and tolerability of the TIL regimen. The study will also test how well TIL fights cancer. The study will enroll children, teenagers, and young adults with solid tumors that have returned or are not responding to treatment for whom no effective standard-of-care treatment options exist.
Study details include:
- The study will last up to 2 years after the TIL infusion (Day 0) for each person.
- The treatment will last up to 10 days for each person.
- Study visits will be every 2 weeks until Day 42, every 6 weeks until Month 6, and every 3 months until Year 2.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 6 Months 至 21 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Participant is ≥ 8 kg and ≤ 21 years of age at the time of informed consent and assent.
- •Histologically or cytologically confirmed recurrent or refractory solid tumor (Rhabdomyosarcoma, Ewing sarcoma, primary CNS malignancies, melanoma) after standard therapy which has failed all available curative therapy.
- •Acceptable performance status and an estimated life expectancy of > 6 months.
- •At least one resectable lesion (solitary or aggregate lesions) for TIL generation.
- •Following tumor resection for TIL generation, the participant will have at least one remaining measurable lesion for response assessment.
- •Preplanned surgical procedure(s) will take place at least 14 days (for major operative procedures) prior to the tumor resection.
- •All prior anticancer treatment-related AEs should be recovered, exceptions are peripheral neuropathy, alopecia, vitiligo, or medically controlled endocrine dysfunction.
- •Agreement to abide by the protocol indicated contraception use, including refraining from donating sperm or eggs (ova, oocytes), as appropriate for the age and sexual activity of pediatric, adolescent, and young adult participants and as required by local regulations.
- •Signed informed consent and assent when applicable.
- •Written authorization for use and disclosure of protected health information.
- •Ability to adhere to the study visit schedule and other protocol requirements.
- •Acceptable hematologic parameters.
- •Adequate organ function.
- •Modified Ross criteria class 1 and an LVFS > 25% or an LVEF ≥ 50%.
- •Adequate pulmonary function.
- •Participant and/or the legal guardian who provided consent is willing for the participant to receive optimal supportive care.
- •A legal guardian or primary caregiver must be available to help the study-site personnel ensure follow-up and accompany the participant to the study site on each assessment day according to the SoA.
排除标准
- •Participant with a non-CNS tumor has symptomatic untreated brain metastases and/or carcinomatous meningitis.
- •Participant has an active or uncontrolled intercurrent illness(es) that would pose increased risks for study participation.
- •Participants are not eligible if they experience uncontrolled seizures.
- •Participants with history of intracranial hemorrhage/spinal cord hemorrhage.
- •Participant has active uveitis that requires active treatment.
- •Participant has significant psychiatric disease or substance abuse in the investigator's opinion that would prevent adequate informed consent.
- •Participant has any form of primary or acquired immunodeficiency.
- •History of clinically significant chronic obstructive pulmonary disease, asthma, interstitial lung disease, or other chronic lung disease.
- •History of hypersensitivity reaction to any components of the study intervention.
- •Any other condition that in the investigator's judgment would significantly increase the risks of participation.
- •Any complication or delayed healing from an excisional procedure that in the investigator's opinion would increase the risks of participation.
- •Another primary malignancy within the previous 3 years.
- •History of allogeneic cell or organ transplant.
- •Requiring systemic steroid therapy higher than the physiologic replacement dose.
- •Received or will receive a live or attenuated vaccination within 28 days prior to the start of the NMA-LD.
- •Any active viral, bacterial, or fungal infection requiring ongoing systemic treatment.
研究组 & 干预措施
Rhabdomyosarcoma (RMS)
Experimental
干预措施: LN-145/LN-144 (Biological)
Ewing Sarcoma (EWS)
Experimental
干预措施: LN-145/LN-144 (Biological)
Primary Central Nervous System Tumor
Experimental
干预措施: LN-145/LN-144 (Biological)
Melanoma
Experimental
干预措施: LN-145/LN-144 (Biological)
结局指标
主要结局
Incidence rate of Treatment-Emergent Adverse Events
时间窗: Up to 24 months
To evaluate the safety and tolerability of the TIL regimen that occurs from the start of TIL infusion and up to 30 days after TIL infusion per CTCAE.
次要结局
- Progression-Free Survival(Up to 24 months)
- Objective Response Rate(Up to 24 months)
- Duration of Response(Up to 24 months)
- Disease Control Rate(Up to 24 months)
- Overall Survival(Up to 24 months)
研究者
研究点 (7)
Loading locations...
相似试验
已完成
2 期
Efficacy and Safety of Tislelizumab in Combination With Fruquintinib in Participants With Selected Solid TumorsNCT04716634BeiGene84
已完成
1 期
A Study to Evaluate the Safety and Efficacy of Therapeutic Hepatitis B VaccineHepatitis B, ChronicNCT02693652CHA Vaccine Institute Co., Ltd.53
招募中
1 期
A Clinical Study of SHR-3276 for Injection in Patients With Advanced Malignant TumorsAdvanced Solid TumorsNCT06643754Suzhou Suncadia Biopharmaceuticals Co., Ltd.115
终止
1 期
A Study of Mitoxantrone Hydrochloride Liposome Injection in Subjects With Acute Myeloid LeukemiaRelapsed or Refractory Acute Myeloid Leukemia (AML)NCT05345938CSPC ZhongQi Pharmaceutical Technology Co., Ltd.1
招募中
1 期
Clinical Study of PM1003 in Phase I/IIa Treatment of Advanced Malignant Solid TumorsAdvanced Solid TumorsNCT05862831Biotheus Inc.285